Article Title: Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials
Authors: Nitika Sharma, Pooja Poorva Bindal, Mimi Najjar, Kelly Koehn, Amandeep Godara, Douglas W. Sborov, Brian McClune, Kelley Julian, Charlotte Wagner and Ghulam Rehman Mohyuddin
Journal Title: Leukemia & Lymphoma
DOI: https://doi.org/10.1080/10428194.2023.2209682
The author has provided a new reference to be included. Reference 14 has been changed as below:
Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study. Clin Lymphoma Myeloma Leuk. 2021;21(9):e699–e709. doi: 10.1016/j.clml.2021.04.012. Epub 2021 Apr 24. PMID: 34108127.
instead of the reference,
Anderson P, Aptsiauri N, Ruiz-Cabello F, et al. HLA class Iloss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol. 2021;18(3):556–565.
The original article has been corrected and republished.